KaydedilenlerDerginizi ekleyin

Dergiler / Selcuk Dental Journal / 2021 / Cilt: 8 - Sayı: 3

Evaluation of Serum, Saliva and GCF Visfatin Levels in Chronic Periodontitis Patients with Uncontrolled /Controlled Type2 Diabetes Mellitus

Mustafa Cihan YAVUZ
Cenk Fatih ÇANAKÇI
Sayfa
817–823
Yayın Tarihi
2021-12-31
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Significant positive correlations between GCF visfatin levels and GCF TNF-α and IL-1β levels were detected in (uDM+P+) group (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background: Visfatin is a multifaceted protein that plays an important role in diabetes (DM) and periodontitis (CP).
📊
Temel Bulgular & Veri:It has been known that during inflammation, the production of IL-1b, TNF-a can be induced by visfatin.
💡
Sonuç & Katkı:Significant positive correlations between GCF visfatin levels and GCF TNF-α and IL-1β levels were detected in (uDM+P+) group (p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Visfatin · TNF-a · IL1-b

Özet

Background: Visfatin is a multifaceted protein that plays an important role in diabetes (DM) and periodontitis (CP). It has been known that during inflammation, the production of IL-1b, TNF-a can be induced by visfatin. Therefore, visfatin is an important mediator for both diseases. The aim of this study is to investigation of visfatin levels in serum, saliva and GCF samples of non-diabetic periodontitis patients and controlled and uncontrolled diabetic periodontitis patients, and evaluation of the relationship with clinical and biochemical parameters of periodontitis Methods: Study protocol, 5 groups which each one were consisted of 15 subjects were planned: periodontally healthy patients with systemically healthy (DM-P-); patients with systemically healthy and CP (DM-P+), periodontally healthy patients with diabetes (DM+P-), patients with diabetes and CP (DM+P+), patients with uncontrolled diabetes and CP (uDM+P). Serum, saliva and GCF samples were obtained and, levels of visfatin, TNF-α and IL-1β were determined by ELISA. Results: The highest visfatin, TNF-α and IL-1β levels were seen in (uDM+P+) group (p>0.001). Significant positive correlations between GCF visfatin levels and GCF TNF-α and IL-1β levels were detected in (uDM+P+) group (p

Abstract

Background: Visfatin is a multifaceted protein that plays an important role in diabetes (DM) and periodontitis (CP). It has been known that during inflammation, the production of IL-1b, TNF-a can be induced by visfatin. Therefore, visfatin is an important mediator for both diseases. The aim of this study is to investigation of visfatin levels in serum, saliva and GCF samples of non-diabetic periodontitis patients and controlled and uncontrolled diabetic periodontitis patients, and evaluation of the relationship with clinical and biochemical parameters of periodontitis Methods: Study protocol, 5 groups which each one were consisted of 15 subjects were planned: periodontally healthy patients with systemically healthy (DM-P-); patients with systemically healthy and CP (DM-P+), periodontally healthy patients with diabetes (DM+P-), patients with diabetes and CP (DM+P+), patients with uncontrolled diabetes and CP (uDM+P). Serum, saliva and GCF samples were obtained and, levels of visfatin, TNF-α and IL-1β were determined by ELISA. Results: The highest visfatin, TNF-α and IL-1β levels were seen in (uDM+P+) group (p>0.001). Significant positive correlations between GCF visfatin levels and GCF TNF-α and IL-1β levels were detected in (uDM+P+) group (p

🔖

Bu Makaleye Atıf Yap

YAVUZ, M. C., ÇANAKÇI, C. F. (2021). Evaluation of Serum, Saliva and GCF Visfatin Levels in Chronic Periodontitis Patients with Uncontrolled /Controlled Type2 Diabetes Mellitus. Selcuk Dental Journal, Cilt: 8 - Sayı: 3, 817–823. https://ajindex.com/articles/698376

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Gabir, M. M., Hanson, R. L., Dabelea, D., Imperatore, G., Roumain, J., Bennett, P. H., & Knowler, W. C. (2000). The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes care, 23(8), 1108-1112
  2. Löe, H. (1993). Periodontal disease: the sixth complication of diabetes mellitus. Diabetes care, 16(1), 329-334
  3. Genco, R. J. (1992). Host responses in periodontal diseases: current concepts. Journal of periodontology, 63, 338-355
  4. Graves, D. T., & Cochran, D. (2003). The contribution of interleukin‐1 and tumor necrosis factor to periodontal tissue destruction. Journal of periodontology, 74(3), 391-401
  5. Buduneli, N., & Kinane, D. F. (2011). Host‐derived diagnostic markers related to soft tissue destruction and bone degradation in periodontitis. Journal of clinical periodontology, 38, 85-105
  6. Pradeep, A. R., Raghavendra, N. M., Prasad, M. R., Kathariya, R., Patel, S. P., & Sharma, A. (2011). Gingival crevicular fluid and serum visfatin concentration: their relationship in periodontal health and disease. Journal of periodontology, 82(9), 1314-1319
  7. Azamar-Llamas, D., Hernandez-Molina, G., Ramos-Avalos, B., & Furuzawa-Carballeda, J. (2017). Adipokine contribution to the pathogenesis of osteoarthritis. Mediators of inflammation, 2017
  8. Ognjanovic, S., Bao, S., Yamamoto, S. Y., Garibay-Tupas, J., Samal, B., & Bryant-Greenwood, G. D. (2001). Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. Journal of molecular endocrinology, 26(2), 107-118
  9. Moschen, A. R., Kaser, A., Enrich, B., Mosheimer, B., Theurl, M., Niederegger, H., & Tilg, H. (2007). Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. The Journal of Immunology, 178(3), 1748-1758
  10. Hammarstedt, A., Pihlajamäki, J., Rotter Sopasakis, V., Gogg, S., Jansson, P. A., Laakso, M., & Smith, U. (2006). Visfatin is an adipokine, but it is not regulated by thiazolidinediones. The Journal of Clinical Endocrinology & Metabolism, 91(3), 1181-1184
  11. Heo, Y. J., Choi, S. E., Jeon, J. Y., Han, S. J., Kim, D. J., Kang, Y.,. & Kim, H. J. (2019). Visfatin induces inflammation and insulin resistance via the NF-κB and STAT3 signaling pathways in hepatocytes. Journal of diabetes research, 2019
  12. Stastny, J., Bienertova-Vasku, J., & Vasku, A. (2012). Visfatin and its role in obesity development. Diabet